Improving Clinical Outcomes in the
Treatment and Management of PAH
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2017 Fall Forum. If you participated in the live
session, you are not eligible for continuing education credits from
This activity is valid from April 30, 2018 to April 30, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
Actelion Pharmaceuticals US Inc.
Pulmonary Arterial Hypertension (PAH) is a progressive vascular
disorder and though relatively rare, PAH is a very serious, life
threatening condition that worsens over time and for which there is
no cure. Over time, the heart muscle can become so weakened that its
ability to pump enough blood through the body is lost, leading to
heart failure – the most common cause of death for PAH patients.
Approximately half of people diagnosed with PAH will not live past
five years, while those with untreated PAH have an average survival
expectancy of approximately three years following diagnosis.
Additionally, PAH often leads to the onset of co-morbidities
associated with the disease, which not only puts the patient at
higher risk but also increases the costs to the healthcare system.
Early diagnosis and accurate classification are keys to managing
costs. Thankfully advancements in diagnostic criteria, guidelines,
classifications and emerging treatments continue to be updated to
find the best treatment for the severity and individual nature of
the disease in each patient. There are several treatments for PAH
depending on the severity and the patient’s profile. These include
monotherapy and combination therapies that can include prostacyclin/prostacyclin
analogues, endothelin receptor antagonists, and phosphodiesterase-5
Upon Completion of this
activity, participants will be able to:
Identify the recently published
evidence-based treatment guidelines for appropriate management
Explore the PAH risk factors and
clinical classifications for conducting a more accurate
Analyze the strategies to optimize
therapy in patients with PAH as well as the underlying
comorbidities associated with the disease
Assess new clinical data on
treatment approaches for patients not meeting the treatment
goals with the first line of therapy
Discuss effective therapeutic
strategies including sequential combination therapy in patients
||Charles Burger, MD
Professor of Medicine
Mayo Clinic College of Medicine
serves on an advisory board for Actelion Pharmaceuticals
and Gilead Sciences. He also receives research support
from Actelion Pharmaceuticals, Bayer, Gilead Sciences
and United Therapeutics. His presentation has been peer
reviewed for any bias.
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by educational grants from
Actelion Pharmaceuticals US Inc.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue